Header Logo

Connection

Leslie Harrold to Male

Back to Details
This is a "connection" page, showing publications Leslie Harrold has written about Male.
Leslie Harrold
Connection Strength
1.662
Male
  1. Harrold LR, Bingham CO, Pope JE, O'Brien J, Moore PC, Roberts-Toler C, Yu M, Sweet LL, Shelbaya A, Masri KR. Effectiveness of tofacitinib versus tumor necrosis factor inhibitors and in those receiving tofacitinib as different lines of therapy in patients with rheumatoid arthritis: results from the United States CorEvitas Rheumatoid Arthritis Registry. Clin Rheumatol. 2025 Feb; 44(2):635-648.
    View in: PubMed
    Score: 0.057
  2. O'Brien J, Park SH, Blachley T, Marchese M, Middaugh N, Wittstock K, Harrold LR. Disparities in burden of disease in patients with rheumatoid arthritis across racial and ethnic groups. Clin Rheumatol. 2024 Mar; 43(3):921-927.
    View in: PubMed
    Score: 0.054
  3. Harrold LR, Shan Y, Rebello S, Kramer N, Connolly SE, Alemao E, Kelly S, Kremer JM, Rosenstein ED. Disease activity and patient-reported outcomes in patients with rheumatoid arthritis and Sj?gren's syndrome enrolled in a large observational US registry. Rheumatol Int. 2020 Aug; 40(8):1239-1248.
    View in: PubMed
    Score: 0.042
  4. Harrold LR, Shan Y, Rebello S, Kramer N, Connolly SE, Alemao E, Kelly S, Kremer JM, Rosenstein ED. Prevalence of Sj?gren's syndrome associated with rheumatoid arthritis in the USA: an observational study from the Corrona registry. Clin Rheumatol. 2020 Jun; 39(6):1899-1905.
    View in: PubMed
    Score: 0.041
  5. Harrold LR, Shan Y, Connolly SE, Alemao E, Rebello S, Guo L, Kremer JM. Association among anti-citrullinated protein antibody status, erosive disease and healthcare resource utilization in patients with rheumatoid arthritis. Curr Med Res Opin. 2020 02; 36(2):337-342.
    View in: PubMed
    Score: 0.040
  6. Harrold LR, Patel PA, Griffith J, Litman HJ, Feng H, Schlacher CA, Kremer JM. Assessing disease severity in bio-na?ve patients with RA on treatment with csDMARDs: insights from the Corrona Registry. Clin Rheumatol. 2020 Feb; 39(2):391-400.
    View in: PubMed
    Score: 0.040
  7. Harrold LR, Griffith J, Zueger P, Litman HJ, Gershenson B, Islam SS, Barr CJ, Guo D, Fay J, Greenberg JD. Longterm, Real-world Safety of Adalimumab in Rheumatoid Arthritis: Analysis of a Prospective US-based Registry. J Rheumatol. 2020 07 01; 47(7):959-967.
    View in: PubMed
    Score: 0.039
  8. Alemao E, Litman HJ, Connolly SE, Kelly S, Hua W, Rosenblatt L, Rebello S, Kremer JM, Harrold LR. Do Poor Prognostic Factors in Rheumatoid Arthritis Affect Treatment Choices and Outcomes? Analysis of a US Rheumatoid Arthritis Registry. J Rheumatol. 2018 10; 45(10):1353-1360.
    View in: PubMed
    Score: 0.037
  9. Harrold LR, Reed GW, John A, Barr CJ, Soe K, Magner R, Saunders KC, Ruderman EM, Haselkorn T, Greenberg JD, Gibofsky A, Harrington JT, Kremer JM. Cluster-Randomized Trial of a Behavioral Intervention to Incorporate a Treat-to-Target Approach to Care of US Patients With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2018 03; 70(3):379-387.
    View in: PubMed
    Score: 0.036
  10. Harrold LR, Litman HJ, Saunders KC, Dandreo KJ, Gershenson B, Greenberg JD, Low R, Stark J, Suruki R, Jaganathan S, Kremer JM, Yassine M. One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry. Arthritis Res Ther. 2018 01 02; 20(1):2.
    View in: PubMed
    Score: 0.035
  11. Harrold LR, Litman HJ, Connolly SE, Kelly S, Hua W, Alemao E, Rosenblatt L, Rebello S, Kremer JM. Effect of Anticitrullinated Protein Antibody Status on Response to Abatacept or Antitumor Necrosis Factor-a Therapy in Patients with Rheumatoid Arthritis: A US National Observational Study. J Rheumatol. 2018 01; 45(1):32-39.
    View in: PubMed
    Score: 0.035
  12. Harrold LR, Stolshek BS, Rebello S, Collier DH, Mutebi A, Wade SW, Malley W, Greenberg JD, Etzel CJ. Rebound in Measures of Disease Activity and Symptoms in Corrona Registry Patients with Psoriatic Arthritis Who Discontinue Tumor Necrosis Factor Inhibitor Therapy after Achieving Low Disease Activity. J Rheumatol. 2018 01; 45(1):78-82.
    View in: PubMed
    Score: 0.035
  13. Harrold LR, John A, Best J, Zlotnick S, Karki C, Li Y, Greenberg JD, Kremer JM. Impact of rituximab on patient-reported outcomes in patients with rheumatoid arthritis from the US Corrona Registry. Clin Rheumatol. 2017 Sep; 36(9):2135-2140.
    View in: PubMed
    Score: 0.034
  14. Harrold LR, Etzel CJ, Gibofsky A, Kremer JM, Pillinger MH, Saag KG, Schlesinger N, Terkeltaub R, Cox V, Greenberg JD. Sex differences in gout characteristics: tailoring care for women and men. BMC Musculoskelet Disord. 2017 03 14; 18(1):108.
    View in: PubMed
    Score: 0.033
  15. Harrold LR, Stolshek BS, Rebello S, Collier DH, Mutebi A, Wade SW, Malley W, Greenberg JD, Etzel CJ. Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry. Clin Rheumatol. 2017 Apr; 36(4):895-901.
    View in: PubMed
    Score: 0.033
  16. Harrold LR, Litman HJ, Connolly SE, Kelly S, Hua W, Alemao E, Rosenblatt L, Rebello S, Kremer JM. A window of opportunity for abatacept in RA: is disease duration an independent predictor of low disease activity/remission in clinical practice? Clin Rheumatol. 2017 Jun; 36(6):1215-1220.
    View in: PubMed
    Score: 0.033
  17. Harrold LR, Reed GW, Karki C, Magner R, Shewade A, John A, Kremer JM, Greenberg JD. Risk of Infection Associated With Subsequent Biologic Agent Use After Rituximab: Results From a National Rheumatoid Arthritis Patient Registry. Arthritis Care Res (Hoboken). 2016 12; 68(12):1888-1893.
    View in: PubMed
    Score: 0.033
  18. Harrold LR, Reed GW, Solomon DH, Curtis JR, Liu M, Greenberg JD, Kremer JM. Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry. Arthritis Res Ther. 2016 12 01; 18(1):280.
    View in: PubMed
    Score: 0.033
  19. Harrold LR, Reed GW, Kremer JM, Curtis JR, Solomon DH, Hochberg MC, Kavanaugh A, Saunders KC, Shan Y, Spruill TM, Pappas DA, Greenberg JD. Identifying factors associated with concordance with the American College of Rheumatology rheumatoid arthritis treatment recommendations. Arthritis Res Ther. 2016 Apr 26; 18:94.
    View in: PubMed
    Score: 0.031
  20. Schlesinger N, Etzel CJ, Greenberg J, Kremer J, Harrold LR. Gout Prophylaxis Evaluated According to the 2012 American College of Rheumatology Guidelines: Analysis from the CORRONA Gout Registry. J Rheumatol. 2016 05; 43(5):924-30.
    View in: PubMed
    Score: 0.031
  21. Harrold LR, Reed GW, Magner R, Shewade A, John A, Greenberg JD, Kremer JM. Comparative effectiveness and safety of rituximab versus subsequent anti-tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti-tumor necrosis factor therapies in the United States Corrona registry. Arthritis Res Ther. 2015 Sep 18; 17:256.
    View in: PubMed
    Score: 0.030
  22. Harrold LR, Reed GW, Shewade A, Magner R, Saunders KC, John A, Kremer JM, Greenberg JD. Effectiveness of Rituximab for the Treatment of Rheumatoid Arthritis in Patients with Prior Exposure to Anti-TNF: Results from the CORRONA Registry. J Rheumatol. 2015 Jul; 42(7):1090-8.
    View in: PubMed
    Score: 0.029
  23. Harrold LR, Reed GW, Kremer JM, Curtis JR, Solomon DH, Hochberg MC, Greenberg JD. The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor. Ann Rheum Dis. 2015 Feb; 74(2):430-6.
    View in: PubMed
    Score: 0.027
  24. Harrold LR, Gurwitz JH, Briesacher BA. Dr. Harrold, et al reply. J Rheumatol. 2013 Aug; 40(8):1462.
    View in: PubMed
    Score: 0.026
  25. Harrold LR, Mazor KM, Negron A, Ogarek J, Firneno C, Yood RA. Primary care providers' knowledge, beliefs and treatment practices for gout: results of a physician questionnaire. Rheumatology (Oxford). 2013 Sep; 52(9):1623-9.
    View in: PubMed
    Score: 0.026
  26. Harrold LR, Salman C, Shoor S, Curtis JR, Asgari MM, Gelfand JM, Wu JJ, Herrinton LJ. Incidence and prevalence of juvenile idiopathic arthritis among children in a managed care population, 1996-2009. J Rheumatol. 2013 Jul; 40(7):1218-25.
    View in: PubMed
    Score: 0.026
  27. Harrold LR, Briesacher BA, Peterson D, Beard A, Madden J, Zhang F, Gurwitz JH, Soumerai SB. Cost-related medication nonadherence in older patients with rheumatoid arthritis. J Rheumatol. 2013 Feb; 40(2):137-43.
    View in: PubMed
    Score: 0.025
  28. Harrold LR, Mazor KM, Peterson D, Naz N, Firneno C, Yood RA. Patients' knowledge and beliefs concerning gout and its treatment: a population based study. BMC Musculoskelet Disord. 2012 Sep 21; 13:180.
    View in: PubMed
    Score: 0.025
  29. Harrold LR, Peterson D, Beard AJ, Gurwitz JH, Briesacher BA. Time trends in medication use and expenditures in older patients with rheumatoid arthritis. Am J Med. 2012 Sep; 125(9):937.e9-15.
    View in: PubMed
    Score: 0.024
  30. Harrold LR, Harrington JT, Curtis JR, Furst DE, Bentley MJ, Shan Y, Reed G, Kremer J, Greenberg JD. Prescribing practices in a US cohort of rheumatoid arthritis patients before and after publication of the American College of Rheumatology treatment recommendations. Arthritis Rheum. 2012 Mar; 64(3):630-8.
    View in: PubMed
    Score: 0.024
  31. Nitichaikulvatana P, Upchurch KS, Harrold LR. Impact of deficits in gout care on hospitalizations. J Clin Rheumatol. 2011 Oct; 17(7):389-91.
    View in: PubMed
    Score: 0.023
  32. Harrold LR, Mazor KM, Velten S, Ockene IS, Yood RA. Patients and providers view gout differently: a qualitative study. Chronic Illn. 2010 Dec; 6(4):263-71.
    View in: PubMed
    Score: 0.021
  33. Harrold LR, Andrade SE, Briesacher B, Raebel MA, Fouayzi H, Yood RA, Ockene IS. The dynamics of chronic gout treatment: medication gaps and return to therapy. Am J Med. 2010 Jan; 123(1):54-9.
    View in: PubMed
    Score: 0.020
  34. Harrold LR, Andrade SE, Briesacher BA, Raebel MA, Fouayzi H, Yood RA, Ockene IS. Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther. 2009; 11(2):R46.
    View in: PubMed
    Score: 0.019
  35. Harrold LR, Li W, Yood RA, Fuller J, Gurwitz JH. Identification of patients with arthritis and arthritis-related functional limitation using administrative data. J Public Health Manag Pract. 2008 Sep-Oct; 14(5):487-97.
    View in: PubMed
    Score: 0.019
  36. Harrold LR, Liu NY. Polyarteritis nodosa presenting as pancytopenia: case report and review of the literature. Rheumatol Int. 2008 Aug; 28(10):1049-51.
    View in: PubMed
    Score: 0.018
  37. Harrold LR, Savageau JA, Pransky G, Benjamin K. Understanding the role of sex differences in work injuries: implications for primary care practice. Disabil Rehabil. 2008; 30(1):36-43.
    View in: PubMed
    Score: 0.018
  38. Harrold LR, Patterson MK, Andrade SE, Dube T, Go AS, Buist AS, Chan KA, Weller PF, Wechsler ME, Yood RA, Davis KJ, Platt R, Walker AM. Asthma drug use and the development of Churg-Strauss syndrome (CSS). Pharmacoepidemiol Drug Saf. 2007 Jun; 16(6):620-6.
    View in: PubMed
    Score: 0.017
  39. Harrold LR, Saag KG, Yood RA, Mikuls TR, Andrade SE, Fouayzi H, Davis J, Chan KA, Raebel MA, Von Worley A, Platt R. Validity of gout diagnoses in administrative data. Arthritis Rheum. 2007 Feb 15; 57(1):103-8.
    View in: PubMed
    Score: 0.017
  40. Harrold LR, Andrade SE, Go AS, Buist AS, Eisner M, Vollmer WM, Chan KA, Frazier EA, Weller PF, Wechsler ME, Yood RA, Davis KJ, Platt R. Incidence of Churg-Strauss syndrome in asthma drug users: a population-based perspective. J Rheumatol. 2005 Jun; 32(6):1076-80.
    View in: PubMed
    Score: 0.015
  41. Fukui S, Winkelmayer WC, Tedeschi SK, Marrugo J, Guan H, Harrold L, Litman HJ, Shinozaki T, Solomon DH. Disease activity of rheumatoid arthritis and kidney function decline: a large prospective registry study. Ann Rheum Dis. 2025 Feb; 84(2):201-209.
    View in: PubMed
    Score: 0.014
  42. Baker JF, Reed G, Mikuls TR, Thiele GM, Pappas DA, Charles-Schoeman C, Guma M, Harrold LR, Curtis JR, Kremer JM. Metabolic Syndrome, Adipokines, and Response to Advanced Therapies in Rheumatoid Arthritis. Arthritis Rheumatol. 2025 Mar; 77(3):263-271.
    View in: PubMed
    Score: 0.014
  43. Mease PJ, Blachley T, Malatestinic WN, Harrold LR, Dube B, Lisse JR, Bolce RJ, Hunter TM. Effectiveness of bDMARDs in ankylosing spondylitis patients by biologic use: experience from the CorEvitas PsA/SpA Registry. Curr Med Res Opin. 2024 02; 40(2):315-323.
    View in: PubMed
    Score: 0.013
  44. Harrold LR, Esteban J, Lessard D, Yarzebski J, Gurwitz JH, Gore JM, Goldberg RJ. Narrowing gender differences in procedure use for acute myocardial infarction: insights from the Worcester heart attack study. J Gen Intern Med. 2003 Jun; 18(6):423-31.
    View in: PubMed
    Score: 0.013
  45. Harrold LR, Lessard D, Yarzebski J, Gurwitz JH, Gore JM, Goldberg RJ. Age and sex differences in the treatment of patients with initial acute myocardial infarction: a community-wide perspective. Cardiology. 2003; 99(1):39-46.
    View in: PubMed
    Score: 0.013
  46. Harrold LR, Yood RA, Straus W, Andrade SE, Reed JI, Cernieux J, Lewis BE, Gurwitz JH. Challenges of estimating health service utilization for osteoarthritis patients on a population level. J Rheumatol. 2002 Sep; 29(9):1931-6.
    View in: PubMed
    Score: 0.012
  47. Harrold LR, Gurwitz JH, Tate JP, Becker R, Stuart T, Elwell A, Radford M. Physician attitudes concerning anticoagulation services in the long-term care setting. J Thromb Thrombolysis. 2002 Aug; 14(1):59-64.
    View in: PubMed
    Score: 0.012
  48. Curtis JR, Palmer JL, Reed GW, Greenberg J, Pappas DA, Harrold LR, Kremer JM. Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2021 08; 73(8):1114-1124.
    View in: PubMed
    Score: 0.011
  49. Owensby JK, Chen L, O'Beirne R, Ruderman EM, Harrold LR, Melnick JA, Safford MM, Curtis JR, Danila MI. Patient and Rheumatologist Perspectives Regarding Challenges to Achieving Optimal Disease Control in Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2020 07; 72(7):933-941.
    View in: PubMed
    Score: 0.011
  50. Van Voorhees AS, Mason MA, Harrold LR, Guo N, Guana A, Tian H, Herrera V, Strober BE. Characterization of insufficient responders to anti-tumor necrosis factor therapies in patients with moderate to severe psoriasis: real-world data from the US Corrona Psoriasis Registry. J Dermatolog Treat. 2021 May; 32(3):302-309.
    View in: PubMed
    Score: 0.010
  51. Solomon DH, Yu Z, Katz JN, Bitton A, Corrigan C, Fraenkel L, Harrold LR, Smolen JS, Losina E, Lu B. Adverse Events and Resource Use Before and After Treat-to-Target in Rheumatoid Arthritis: A Post Hoc Analysis of a Randomized Controlled Trial. Arthritis Care Res (Hoboken). 2019 09; 71(9):1243-1248.
    View in: PubMed
    Score: 0.010
  52. Lillegraven S, Greenberg JD, Reed GW, Saunders K, Curtis JR, Harrold L, Hochberg MC, Pappas DA, Kremer JM, Solomon DH. Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis. PLoS One. 2019; 14(1):e0210459.
    View in: PubMed
    Score: 0.010
  53. Ogdie A, Palmer JL, Greenberg J, Curtis JR, Harrold LR, Solomon DH, Kavanaugh A, Kremer JM, Mease PJ. Predictors of Achieving Remission among Patients with Psoriatic Arthritis Initiating a Tumor Necrosis Factor Inhibitor. J Rheumatol. 2019 05; 46(5):475-482.
    View in: PubMed
    Score: 0.009
  54. Zak A, Corrigan C, Yu Z, Bitton A, Fraenkel L, Harrold L, Smolen JS, Solomon DH. Barriers to treatment adjustment within a treat to target strategy in rheumatoid arthritis: a secondary analysis of the TRACTION trial. Rheumatology (Oxford). 2018 11 01; 57(11):1933-1937.
    View in: PubMed
    Score: 0.009
  55. Solomon DH, Lu B, Yu Z, Corrigan C, Harrold LR, Smolen JS, Fraenkel L, Katz JN, Losina E. Benefits and Sustainability of a Learning Collaborative for Implementation of Treat-to-Target in Rheumatoid Arthritis: Results of a Cluster-Randomized Controlled Phase II Clinical Trial. Arthritis Care Res (Hoboken). 2018 10; 70(10):1551-1556.
    View in: PubMed
    Score: 0.009
  56. Yu Z, Lu B, Agosti J, Bitton A, Corrigan C, Fraenkel L, Harrold LR, Losina E, Katz JN, Solomon DH. Implementation of Treat-to-Target for Rheumatoid Arthritis in the US: Analysis of Baseline Data From a Randomized Controlled Trial. Arthritis Care Res (Hoboken). 2018 05; 70(5):801-806.
    View in: PubMed
    Score: 0.009
  57. Curtis JR, Greenberg JD, Harrold LR, Kremer JM, Palmer JL. Influence of obesity, age, and comorbidities on the multi-biomarker disease activity test in rheumatoid arthritis. Semin Arthritis Rheum. 2018 02; 47(4):472-477.
    View in: PubMed
    Score: 0.009
  58. Solomon DH, Losina E, Lu B, Zak A, Corrigan C, Lee SB, Agosti J, Bitton A, Harrold LR, Pincus T, Radner H, Yu Z, Smolen JS, Fraenkel L, Katz JN. Implementation of Treat-to-Target in Rheumatoid Arthritis Through a Learning Collaborative: Results of a Randomized Controlled Trial. Arthritis Rheumatol. 2017 07; 69(7):1374-1380.
    View in: PubMed
    Score: 0.008
  59. Tatlock S, R?dell K, Panter C, Arbuckle R, Harrold LR, Taylor WJ, Symonds T. What Outcomes are Important for Gout Patients? In-Depth Qualitative Research into the Gout Patient Experience to Determine Optimal Endpoints for Evaluating Therapeutic Interventions. Patient. 2017 02; 10(1):65-79.
    View in: PubMed
    Score: 0.008
  60. Curtis JR, Chen L, Greenberg JD, Harrold L, Kilgore ML, Kremer JM, Solomon DH, Yun H. The clinical status and economic savings associated with remission among patients with rheumatoid arthritis: leveraging linked registry and claims data for synergistic insights. Pharmacoepidemiol Drug Saf. 2017 Mar; 26(3):310-319.
    View in: PubMed
    Score: 0.008
  61. Boytsov N, Harrold LR, Mason MA, Gaich CL, Zhang X, Larmore CJ, Rebello S, Araujo AB. Increased healthcare resource utilization in higher disease activity levels in initiators of TNF inhibitors among US rheumatoid arthritis patients. Curr Med Res Opin. 2016 12; 32(12):1959-1967.
    View in: PubMed
    Score: 0.008
  62. Curtis JR, Harrold LR, Asgari MM, Deodhar A, Salman C, Gelfand JM, Wu JJ, Herrinton LJ. Diagnostic Prevalence of Ankylosing Spondylitis Using Computerized Health Care Data, 1996 to 2009: Underrecognition in a US Health Care Setting. Perm J. 2016; 20(4):15-151.
    View in: PubMed
    Score: 0.008
  63. Rathbun AM, Harrold LR, Reed GW. A Prospective Evaluation of the Effects of Prevalent Depressive Symptoms on Disease Activity in Rheumatoid Arthritis Patients Treated With Biologic Response Modifiers. Clin Ther. 2016 Jul; 38(7):1759-1772.e3.
    View in: PubMed
    Score: 0.008
  64. Curtis JR, Bharat A, Chen L, Greenberg JD, Harrold L, Kremer JM, Sommers T, Pappas D. Agreement between Rheumatologist and Patient-reported Adherence to Methotrexate in a US Rheumatoid Arthritis Registry. J Rheumatol. 2016 06; 43(6):1027-9.
    View in: PubMed
    Score: 0.008
  65. Nguyen UD, Ayers DC, Li W, Harrold LR, Franklin PD. Preoperative Pain and Function: Profiles of Patients Selected for Total Knee Arthroplasty. J Arthroplasty. 2016 11; 31(11):2402-2407.e2.
    View in: PubMed
    Score: 0.008
  66. Navarro-Mill?n I, Herrinton LJ, Chen L, Harrold L, Liu L, Curtis JR. Comparative Effectiveness of Etanercept and Adalimumab in Patient Reported Outcomes and Injection-Related Tolerability. PLoS One. 2016; 11(3):e0149781.
    View in: PubMed
    Score: 0.008
  67. Liu SH, Driban JB, Eaton CB, McAlindon TE, Harrold LR, Lapane KL. Objectively Measured Physical Activity and Symptoms Change in Knee Osteoarthritis. Am J Med. 2016 05; 129(5):497-505.e1.
    View in: PubMed
    Score: 0.008
  68. Herrinton LJ, Harrold L, Salman C, Liu L, Goldfien R, Asgari M, Gelfand JM, Wu JJ, Curtis JR. Population Variations in Rheumatoid Arthritis Treatment and Outcomes, Northern California, 1998-2009. Perm J. 2016; 20(1):4-12.
    View in: PubMed
    Score: 0.008
  69. Rathbun AM, Harrold LR, Reed GW. Temporal effect of depressive symptoms on the longitudinal evolution of rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken). 2015 May; 67(6):765-75.
    View in: PubMed
    Score: 0.007
  70. Curtis JR, Chen L, Bharat A, Delzell E, Greenberg JD, Harrold L, Kremer J, Setoguchi S, Solomon DH, Xie F, Yun H. Linkage of a de-identified United States rheumatoid arthritis registry with administrative data to facilitate comparative effectiveness research. Arthritis Care Res (Hoboken). 2014 Dec; 66(12):1790-8.
    View in: PubMed
    Score: 0.007
  71. Rathbun AM, Harrold LR, Reed GW. Temporal associations between the different domains of rheumatoid arthritis disease activity and the onset of patient-reported depressive symptoms. Clin Rheumatol. 2015 Apr; 34(4):653-63.
    View in: PubMed
    Score: 0.007
  72. Rathbun AM, Harrold LR, Reed GW. A description of patient- and rheumatologist-reported depression symptoms in an American rheumatoid arthritis registry population. Clin Exp Rheumatol. 2014 Jul-Aug; 32(4):523-32.
    View in: PubMed
    Score: 0.007
  73. Gurwitz JH, Field TS, Ogarek J, Tjia J, Cutrona SL, Harrold LR, Gagne SJ, Preusse P, Donovan JL, Kanaan AO, Reed G, Garber L. An electronic health record-based intervention to increase follow-up office visits and decrease rehospitalization in older adults. J Am Geriatr Soc. 2014 May; 62(5):865-71.
    View in: PubMed
    Score: 0.007
  74. Curtis JR, Shan Y, Harrold L, Zhang J, Greenberg JD, Reed GW. Patient perspectives on achieving treat-to-target goals: a critical examination of patient-reported outcomes. Arthritis Care Res (Hoboken). 2013 Oct; 65(10):1707-12.
    View in: PubMed
    Score: 0.007
  75. Kanaan AO, Donovan JL, Duchin NP, Field TS, Tjia J, Cutrona SL, Gagne SJ, Garber L, Preusse P, Harrold LR, Gurwitz JH. Adverse drug events after hospital discharge in older adults: types, severity, and involvement of Beers Criteria Medications. J Am Geriatr Soc. 2013 Nov; 61(11):1894-9.
    View in: PubMed
    Score: 0.007
  76. Solomon DH, Kremer JM, Fisher M, Curtis JR, Furer V, Harrold LR, Hochberg MC, Reed G, Tsao P, Greenberg JD. Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs. Semin Arthritis Rheum. 2014 Feb; 43(4):489-97.
    View in: PubMed
    Score: 0.007
  77. Solomon DH, Curtis JR, Saag KG, Lii J, Chen L, Harrold LR, Herrinton LJ, Graham DJ, Kowal MK, Kuriya B, Liu L, Griffin MR, Lewis JD, Rassen JA. Cardiovascular risk in rheumatoid arthritis: comparing TNF-a blockade with nonbiologic DMARDs. Am J Med. 2013 Aug; 126(8):730.e9-730.e17.
    View in: PubMed
    Score: 0.007
  78. Spruill TM, Ogedegbe G, Harrold LR, Potter J, Scher JU, Rosenthal PB, Greenberg JD. Association of medication beliefs and self-efficacy with adherence in urban Hispanic and African-American rheumatoid arthritis patients. Ann Rheum Dis. 2014 Jan; 73(1):317-8.
    View in: PubMed
    Score: 0.007
  79. Asgari MM, Wu JJ, Gelfand JM, Salman C, Curtis JR, Harrold LR, Herrinton LJ. Validity of diagnostic codes and prevalence of psoriasis and psoriatic arthritis in a managed care population, 1996-2009. Pharmacoepidemiol Drug Saf. 2013 Aug; 22(8):842-9.
    View in: PubMed
    Score: 0.006
  80. Prowse RL, Dalbeth N, Kavanaugh A, Adebajo AO, Gaffo AL, Terkeltaub R, Mandell BF, Suryana BP, Goldenstein-Schainberg C, Diaz-Torne C, Khanna D, Liot? F, Mccarthy G, Kerr GS, Yamanaka H, Janssens H, Baraf HF, Chen JH, Vazquez-Mellado J, Harrold LR, Stamp LK, Van De Laar MA, Janssen M, Doherty M, Boers M, Edwards NL, Gow P, Chapman P, Khanna P, Helliwell PS, Grainger R, Schumacher HR, Neogi T, Jansen TL, Louthrenoo W, Sivera F, Taylor WJ, Alten R. A delphi exercise to identify characteristic features of gout - opinions from patients and physicians, the first stage in developing new classification criteria. J Rheumatol. 2013 Apr; 40(4):498-505.
    View in: PubMed
    Score: 0.006
  81. Herrinton LJ, Harrold LR, Liu L, Raebel MA, Taharka A, Winthrop KL, Solomon DH, Curtis JR, Lewis JD, Saag KG. Association between anti-TNF-a therapy and interstitial lung disease. Pharmacoepidemiol Drug Saf. 2013 Apr; 22(4):394-402.
    View in: PubMed
    Score: 0.006
  82. Solomon DH, Rassen JA, Kuriya B, Chen L, Harrold LR, Graham DJ, Lewis JD, Lii J, Liu L, Griffin MR, Curtis JR. Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist. Ann Rheum Dis. 2013 Nov; 72(11):1813-8.
    View in: PubMed
    Score: 0.006
  83. Herrinton LJ, Liu L, Chen L, Harrold LR, Raebel MA, Curtis JR, Griffin MR, Solomon DH, Saag KG, Lewis JD. Association between anti-TNF-a therapy and all-cause mortality. Pharmacoepidemiol Drug Saf. 2012 Dec; 21(12):1311-20.
    View in: PubMed
    Score: 0.006
  84. Tjia J, Field TS, Mazor KM, Donovan JL, Kanaan AO, Reed G, Doherty P, Harrold LR, Gurwitz JH. Dementia and risk of adverse warfarin-related events in the nursing home setting. Am J Geriatr Pharmacother. 2012 Oct; 10(5):323-30.
    View in: PubMed
    Score: 0.006
  85. Fisher MC, Furer V, Hochberg MC, Greenberg JD, Kremer JM, Curtis JR, Reed G, Harrold L, Solomon DH. Malignancy validation in a United States registry of rheumatoid arthritis patients. BMC Musculoskelet Disord. 2012 May 31; 13:85.
    View in: PubMed
    Score: 0.006
  86. Toh S, Li L, Harrold LR, Bayliss EA, Curtis JR, Liu L, Chen L, Grijalva CG, Herrinton LJ. Comparative safety of infliximab and etanercept on the risk of serious infections: does the association vary by patient characteristics? Pharmacoepidemiol Drug Saf. 2012 May; 21(5):524-34.
    View in: PubMed
    Score: 0.006
  87. Greenberg JD, Reed G, Decktor D, Harrold L, Furst D, Gibofsky A, Dehoratius R, Kishimoto M, Kremer JM. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis. 2012 Jul; 71(7):1134-42.
    View in: PubMed
    Score: 0.006
  88. Furst DE, Pangan AL, Harrold LR, Chang H, Reed G, Kremer JM, Greenberg JD. Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: results from the Consortium of Rheumatology Researchers of North America registry. Arthritis Care Res (Hoboken). 2011 Jun; 63(6):856-64.
    View in: PubMed
    Score: 0.006
  89. Field TS, Tjia J, Mazor KM, Donovan JL, Kanaan AO, Harrold LR, Reed G, Doherty P, Spenard A, Gurwitz JH. Randomized trial of a warfarin communication protocol for nursing homes: an SBAR-based approach. Am J Med. 2011 Feb; 124(2):179.e1-7.
    View in: PubMed
    Score: 0.005
  90. Briesacher BA, Andrade SE, Harrold LR, Fouayzi H, Yood RA. Adherence and occurrence of fractures after switching to once-monthly oral bisphophonates. Pharmacoepidemiol Drug Saf. 2010 Dec; 19(12):1233-40.
    View in: PubMed
    Score: 0.005
  91. Briesacher BA, Andrade SE, Harrold LR, Fouayzi H, Yood RA. Adoption of once-monthly oral bisphosphonates and the impact on adherence. Am J Med. 2010 Mar; 123(3):275-80.
    View in: PubMed
    Score: 0.005
  92. Curtis JR, Chen L, Harrold LR, Narongroeknawin P, Reed G, Solomon DH. Physician preference motivates the use of anti-tumor necrosis factor therapy independent of clinical disease activity. Arthritis Care Res (Hoboken). 2010 Jan 15; 62(1):101-7.
    View in: PubMed
    Score: 0.005
  93. Greenberg JD, Harrold LR, Bentley MJ, Kremer J, Reed G, Strand V. Evaluation of composite measures of treatment response without acute-phase reactants in patients with rheumatoid arthritis. Rheumatology (Oxford). 2009 Jun; 48(6):686-90.
    View in: PubMed
    Score: 0.005
  94. Gurwitz JH, Field TS, Rochon P, Judge J, Harrold LR, Bell CM, Lee M, White K, LaPrino J, Erramuspe-Mainard J, DeFlorio M, Gavendo L, Baril JL, Reed G, Bates DW. Effect of computerized provider order entry with clinical decision support on adverse drug events in the long-term care setting. J Am Geriatr Soc. 2008 Dec; 56(12):2225-33.
    View in: PubMed
    Score: 0.005
  95. Gurwitz JH, Field TS, Radford MJ, Harrold LR, Becker R, Reed G, DeBellis K, Moldoff J, Verzier N. The safety of warfarin therapy in the nursing home setting. Am J Med. 2007 Jun; 120(6):539-44.
    View in: PubMed
    Score: 0.004
  96. Raebel MA, McClure DL, Simon SR, Chan KA, Feldstein AC, Gunter MJ, Lafata JE, Harrold L, Nelson WW, Platt R. Frequency of serum creatinine monitoring during allopurinol therapy in ambulatory patients. Ann Pharmacother. 2006 Mar; 40(3):386-91.
    View in: PubMed
    Score: 0.004
  97. Sciamanna CN, Harrold LR, Manocchia M, Walker NJ, Mui S. The effect of web-based, personalized, osteoarthritis quality improvement feedback on patient satisfaction with osteoarthritis care. Am J Med Qual. 2005 May-Jun; 20(3):127-37.
    View in: PubMed
    Score: 0.004
  98. Gurwitz JH, Field TS, Judge J, Rochon P, Harrold LR, Cadoret C, Lee M, White K, LaPrino J, Erramuspe-Mainard J, DeFlorio M, Gavendo L, Auger J, Bates DW. The incidence of adverse drug events in two large academic long-term care facilities. Am J Med. 2005 Mar; 118(3):251-8.
    View in: PubMed
    Score: 0.004
  99. Sacks JJ, Harrold LR, Helmick CG, Gurwitz JH, Emani S, Yood RA. Validation of a surveillance case definition for arthritis. J Rheumatol. 2005 Feb; 32(2):340-7.
    View in: PubMed
    Score: 0.004
  100. Field TS, Gurwitz JH, Harrold LR, Rothschild J, DeBellis KR, Seger AC, Auger JC, Garber LA, Cadoret C, Fish LS, Garber LD, Kelleher M, Bates DW. Risk factors for adverse drug events among older adults in the ambulatory setting. J Am Geriatr Soc. 2004 Aug; 52(8):1349-54.
    View in: PubMed
    Score: 0.003
  101. Gurwitz JH, Field TS, Harrold LR, Rothschild J, Debellis K, Seger AC, Cadoret C, Fish LS, Garber L, Kelleher M, Bates DW. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003 Mar 05; 289(9):1107-16.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.